141 related articles for article (PubMed ID: 36854497)
1. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
Wagner SM; Magnes T; Melchardt T; Kiem D; Weiss L; Neureiter D; Wagner C; Aretin MB; Nemec S; Gamerith G; Pall G; Greil R; Fuereder T
Anticancer Res; 2023 Mar; 43(3):1273-1282. PubMed ID: 36854497
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
4. Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T; Fushimi C; Matsuki T; Tokashiki K; Takahashi H; Okamoto I; Sato H; Kondo T; Hanyu K; Kishida T; Ito T; Yamashita G; Masubuchi T; Tada Y; Miura K; Omura GO; Yamashita T; Oridate N; Tsukahara K
Anticancer Res; 2023 Jun; 43(6):2717-2724. PubMed ID: 37247908
[TBL] [Abstract][Full Text] [Related]
5. The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
Thapa A; Cowell A; Peters A; Noble DJ; James A; Lamb C; Grose D; Vohra S; Schipani S; Mactier K; Mackenzie J; Srinivasan D; Laws K; Moleron R; Niblock P; Soh FY; Paterson C; Wilson C
Clin Oncol (R Coll Radiol); 2024 May; 36(5):287-299. PubMed ID: 38395634
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
8. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N
Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457
[TBL] [Abstract][Full Text] [Related]
9. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
12. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
14. Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Sato M; Enokida T; Wada A; Okano S; Tanaka H; Fujisawa T; Ueda Y; Motegi A; Shinozaki T; Takeshita N; Tanaka N; Zenda S; Matsuura K; Akimoto T; Hayashi R; Tahara M
Int J Clin Oncol; 2023 Aug; 28(8):1023-1032. PubMed ID: 37344738
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
Abraham P; Kish JK; Korytowsky B; Radtchenko J; Singh P; Shaw J; Feinberg B
J Med Econ; 2020 Feb; 23(2):125-131. PubMed ID: 31581922
[No Abstract] [Full Text] [Related]
16. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
17. [The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Yokota T
Gan To Kagaku Ryoho; 2019 Jan; 46(1):21-27. PubMed ID: 30765636
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
[TBL] [Abstract][Full Text] [Related]
19. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T; Fushimi C; Matsuki T; Okamoto I; Sato H; Kondo T; Tokashiki K; Kishida T; Ito T; Yamashita G; Aihara Y; Hanyu K; Kushihashi Y; Masubuchi T; Tada Y; Miura K; Harada Y; Momiyama K; Yamashita T; Omura GO; Takahashi H; Oridate N; Tsukahara K
Anticancer Res; 2022 Mar; 42(3):1607-1613. PubMed ID: 35220258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
